1,170 results on '"Baraliakos, X."'
Search Results
2. Häufigkeit und Schweregrad von Sarkopenie bei Patient*innen mit entzündlichen und nichtentzündlichen muskuloskeletalen Erkrankungen: Ergebnisse einer monozentrischen Studie in einem tertiären Zentrum
3. Wie viele Patienten mit entzündlich rheumatischen Erkrankungen haben die technischen Voraussetzungen für Videosprechstunden und sind bereit, fachärztliche Visiten so durchzuführen?
4. Treatment overview of axial spondyloarthritis in 2023
5. Entwicklung von Qualitätsstandards für Patient*innen mit axialer Spondyloarthritis zum Einsatz in Deutschland
6. Management of Axial Spondyloarthritis – Insights into Upadacitinib
7. AB0876 PREVALENCE OF SPONDYLOARTHRITIS-RELATED LESIONS AT SACROILIAC JOINTS IN POSTPARTUM WOMEN AND INFLAMMATORY BOWEL DISEASE PATIENTS
8. POS0029 ENHANCING THE DIAGNOSTIC ACCURACY AND AVOIDING OVERDIAGNOSIS IN AXIAL SPONDYLOARTHRITIS THROUGH CENTRAL EVALUATION OF IMAGING: IMPROVE-axSpA, A NATIONWIDE TELEMEDICINE PROJECT
9. POS0249 ASSOCIATIONS BETWEEN CLINICAL CHARACTERISTICS AND SCREENING MRI FINDINGS: EXPLORATORY ANALYSIS OF THE ONGOING PHASE 4, MULTICENTER, RANDOMIZED, CONTROLLED STAR STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH PsA WITH MRI-CONFIRMED AXIAL INVOLVEMENT
10. OP0213 Ly6G+CXCR2-CD101- GRANULOCYTES REGULATE INFLAMMATION IN AXIAL SPONDYLOARTHRITIS
11. POS0505 EVALUATING HEALTH UTILITIES BASED ON ASAS HEALTH INDEX IN SPONDYLOARTHRITIS: AN ANCILLARY ANALYSIS FROM THE ASAS-HI INTERNATIONAL VALIDATION STUDY
12. AB0902 RATES OF REMISSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED IN TERTIARY CARE
13. OP0248 MAGNETIC RESONANCE IMAGING OF SHOULDER GIRDLE IN POLYMYALGIA RHEUMATICA – INFLAMMATORY FINDINGS AND THEIR DIAGNOSTIC VALUE
14. LBA0003 MINIMAL SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY
15. POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
16. POS0050 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 SELECT-AXIS 2 STUDY
17. OP0284 FREQUENCY AND FACTORS ASSOCIATED WITH THE PRESENCE OF ACTIVE INFLAMMATORY AND STRUCTURAL CHANGES IN THE MRI OF SACROILIAC JOINTS: RESULTS FROM A POPULATION-BASED STUDY
18. AB0889 TOPOGRAPHICAL, VOLUMENTRIC AND SUBGROUP DIFFERENTIATION BETWEEN INFLAMMATORY SIJ LESIONS ON MRIS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND CHRONIC LOW BACK PAIN
19. AB1486 BASELINE CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISORDERS: DATA FROM A PROSPECTIVE OBSERVATIONAL COHORT FROM THE GERMAN REGISTRY LORE
20. POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY
21. POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION
22. POS0901 FACTORS ASSOCIATED WITH SUICIDAL IDEATION AMONG PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASES: A CASE-CONTROL STUDY
23. POS0497 EFFECT OF DEPRESSIVE SYMPTOMS ON REMISSION IN axSpA PATIENTS: AN ANALYSIS FROM THE RABBIT-SpA COHORT
24. AB0969 SIGNIFICANT RELATIONSHIP OF TRACE ELEMENTS WITH OBJECTIVE SERUM INFLAMMATORY MARKERS IN SPONDYLOARTHRITIS
25. POS0038 ANATOMICAL DISTRIBUTION OF MRI LESIONS IN axSpA AND DIFFERENCES BETWEEN PATIENTS WITH AND WITHOUT PERIPHERAL INVOLVEMENT: RESULTS FROM THE ASAS CLASSIFICATION COHORT
26. POS0058 IMPACT OF BIMEKIZUMAB ON MRI INFLAMMATORY AND STRUCTURAL LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS AND POST HOC ANALYSES FROM THE BE MOBILE 1 AND 2 PHASE 3 STUDIES
27. POS0798 EFFICACY, SAFETY AND RADIOGRAPHIC OUTCOMES FROM THE PHASE 3 SELECT-AXIS 2 STUDY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: 2-YEAR DATA
28. LBA0006 SECUKINUMAB VERSUS STANDARD-OF-CARE IN AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED OPEN-LABEL TRIAL FOR TREAT-TO-TARGET OUTCOMES (ASCALATE)
29. AB1443 CONSISTENT SAFETY PROFILE OF SECUKINUMAB IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: UPDATE ON THE DATA FROM POOLED CLINICAL TRIALS
30. Beantwortung epidemiologisch-rheumatologischer Fragestellungen durch Kooperation mit der bevölkerungsbasierten SHIP-Kohorte – Erkenntnisse für die Diagnostik der axialen Spondyloarthritis (axSpA)
31. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial
32. Striking sex differences in magnetic resonance imaging findings in the sacroiliac joints in the population
33. Sind SARS-CoV-2-reaktive T‑Zellen bei Patienten unter Anti-CD20-Therapie mit einer beeinträchtigten humoralen Antwort nachweisbar und potenziell protektiv?
34. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
35. Das 'KOBRA-Qualitätsprojekt' in der akutstationären Rheumatologie
36. Geschlechtsunterschiede bei Patient:innen mit Psoriasis-Arthritis im Krankheitsregister RABBIT-SpA
37. Differenzialdiagnose der Rückenschmerzen einschließlich Brachialgien und Ischialgien
38. Le bimékizumab permet le maintien des réponses cliniques évaluées par des critères stricts jusqu’à la semaine 52 chez les patients atteints de spondyloarthrite axiale : résultats des études de phase III BE MOBILE 1 et BE MOBILE 2
39. Tolérance et efficacité à long terme du bimékizumab chez les patients atteints de spondylarthrite ankylosante active : résultats à 5 ans d’une étude de phase IIb et de son extension en ouvert
40. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : analyse en sous-groupes avec sur le statut syndesmophytes et protéine C-réactive à l’inclusion
41. Le bimékizumab réduit les lésions inflammatoires à l’IRM chez les patients atteints de spondyloarthrite axiale : résultats à la semaine 52 des études de phase III BE MOBILE 1 et 2
42. Effet du sécukinumab versus adalimumab biosimilaire sur la progression radiographique chez les patients atteints de spondyloarthrite axiale radiographique : étude randomisée de phase 3b
43. Chevauchement significatif de caractéristiques inflammatoires et dégénératives à l’imagerie chez les patients atteints de pathologie dégénérative du rachis, d’hyperostose squelettique idiopathique diffuse et de spondylarthrite axiale radiographique
44. Améliorations cliniquement significatives des critères-patient sous guselkumab chez les patients atteints de rhumatisme psoriasique actif en réponse inadéquate aux anti-TNF : résultats à un an d’une étude de phase 3b, randomisée, contrôlée (COSMOS)
45. Evaluation des Trabecular Bone Score (TBS) in der täglichen Praxis bei Patienten mit entzündlich rheumatischen und nichtentzündlichen Erkrankungen: Korrelation mit konventioneller Knochendichtemessung und Prävalenz von Wirbelkörperfrakturen
46. Recommendation for the Management of Spondyloarthritis Patients in Kuwait
47. Wie gut sind Patienten mit entzündlich rheumatischen Erkrankungen gegen Masern geschützt?
48. Aktueller Stand, Ziele und Qualitätsstandards der ambulanten Versorgung in der Rheumatologie: Positionspapier des Berufsverbandes der deutschen Rheumatologen (BDRh)
49. Klinische Wertigkeit der Bestimmung von DFS70-Antikörpern für den Ausschluss von Kollagenosen
50. Biosimilars und der Nocebo-Effekt
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.